Apellis Pharmaceuticals Email Format

Biotechnology ResearchMassachusetts, United States501-1000 Employees

At Apellis, we are committed to developing transformative therapies for people living with a broad range of debilitating diseases by controlling complement, part of the body’s immune system. Our work is rooted centrally at C3, which is the only target in the complement cascade that addresses all three pathways that can drive disease. Targeting C3 has broad platform potential to treat many diseases where patients have few or no treatment options available. Our programs across ophthalmology, nephrology, hematology, and neurology are further exploring what is possible by targeting C3. You can view our community guidelines here: Community guidelines: http://bit.ly/476Q8

✕

Access Insights for Apellis Pharmaceuticals and Millions of Other Companies

Sign up for full access to Apellis Pharmaceuticals information.

Continue with GoogleContinue with Microsoft

No credit card needed

OR

Work email

Create AccountBy creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.

Sign up for free to view info

Company overview Employee directory